Zimmer Biomet Holdings (NYSE:ZBH) has tumbled 2.31% during the past week and has dropped 2.39% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 1.13%. Zimmer Biomet Holdings (NYSE:ZBH) has underperformed the index by 3.28% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Zimmer Biomet Holdings (NYSE:ZBH): The stock opened at $116.67 on Friday but the bulls could not build on the opening and the stock topped out at $116.88 for the day. The stock traded down to $115.45 during the day, due to lack of any buying support eventually closed down at $116.48 with a loss of -0.20% for the day. The stock had closed at $116.71 on the previous day. The total traded volume was 2,234,644 shares.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Collins Tony W., officer (VP, Controller and CAO) of Zimmer Biomet Holdings, Inc., had unloaded 3,611 shares at an average price of $116.43 in a transaction dated on June 14, 2016. The total value of the transaction was worth $420,429.
Many analysts have stated their opinion on the company shares. Guggenheim Securities initiates coverage on Zimmer Biomet Holdings (NYSE:ZBH). The shares have now been rated Neutral by the stock experts at the ratings house. The rating by the firm was issued on June 9, 2016. Currently the company Insiders own 1.22% of Zimmer Biomet Holdings shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -43.64% . Institutional Investors own 90.52% of Zimmer Biomet Holdings shares. During last six month period, the net percent change held by insiders has seen a change of -43.64%.
Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc. is a musculoskeletal healthcare company. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company manages its operations through three geographic segments: the Americas, comprising principally of the United States and includes other North, Central and South American markets; Europe, comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific, comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions, such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers, and directly to dental practices and dental laboratories.